Scholarlink

Background: <p>Fumarate hydratase-deficient renal cell carcinoma (FHd-RCC) is a rare and aggressive renal cancer subtype characterised by increased fumarate accumulation and upregulated lactate production. Renal tumours demonstrate significant intratumoral metabolic heterogeneity, which may contribute to treatment failure. Emerging non-invasive metabolic imaging techniques have clinical potential to more accurately phenotype tumour metabolism and its heterogeneity.</p> Methods: <p>In this case study we have used hyperpolarised <sup>13</sup>C-pyruvate MRI (HP <sup>13</sup>C-MRI) to assess <sup>13</sup>C-lactate generation in a patient with an organ-confined FHd-RCC. Post-operative tissue samples were co-registered with imaging and underwent sequencing, IHC staining, and mass spectrometry imaging (MSI).</p> Results: <p>HP <sup>13</sup>C-MRI reveals two metabolically distinct tumour regions. The <sup>13</sup>C-lactate-rich region shows a high lactate/pyruvate ratio and slightly lower fumarate on MSI compared to the other tumour region, as well as increased CD8 + T cell infiltration, and genetic dedifferentiation. Compared to the normal kidney, the vascularity in the tumour is decreased, while immune cell fraction is markedly higher.</p> Conclusions: <p>This study shows the potential of metabolic HP <sup>13</sup>C-MRI to characterise FHd-RCC and how targeting of biopsies to regions of metabolic dysregulation could be used to obtain the tumour samples of greatest clinical significance, which in turn can inform on early and successful response to treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Probing intratumoral metabolic compartmentalisation in a patient with fumarate hydratase-deficient renal cancer using clinical hyperpolarised 13C-MRI and mass spectrometry imaging

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月13日

查看全文
  • Ines Horvat-Menih,
  • Ruth Casey,
  • James Denholm,
  • Gregory Hamm,
  • Heather Hulme,
  • John Gallon,
  • Alixander S. Khan,
  • Joshua Kaggie,
  • Andrew B. Gill,
  • Andrew N. Priest,
  • Joao A. G. Duarte,
  • Cissy Yong,
  • Cara Brodie,
  • James Whitworth,
  • Simon T. Barry,
  • Richard J. A. Goodwin,
  • Shubha Anand,
  • Marc Dodd,
  • Katherine Honan,
  • Sarah J. Welsh,
  • Anne Y. Warren,
  • Tevita Aho,
  • Grant D. Stewart,
  • Thomas J. Mitchell,
  • Mary A. McLean,
  • Ferdia A. Gallagher

摘要

Background:

Fumarate hydratase-deficient renal cell carcinoma (FHd-RCC) is a rare and aggressive renal cancer subtype characterised by increased fumarate accumulation and upregulated lactate production. Renal tumours demonstrate significant intratumoral metabolic heterogeneity, which may contribute to treatment failure. Emerging non-invasive metabolic imaging techniques have clinical potential to more accurately phenotype tumour metabolism and its heterogeneity.

Methods:

In this case study we have used hyperpolarised 13C-pyruvate MRI (HP 13C-MRI) to assess 13C-lactate generation in a patient with an organ-confined FHd-RCC. Post-operative tissue samples were co-registered with imaging and underwent sequencing, IHC staining, and mass spectrometry imaging (MSI).

Results:

HP 13C-MRI reveals two metabolically distinct tumour regions. The 13C-lactate-rich region shows a high lactate/pyruvate ratio and slightly lower fumarate on MSI compared to the other tumour region, as well as increased CD8 + T cell infiltration, and genetic dedifferentiation. Compared to the normal kidney, the vascularity in the tumour is decreased, while immune cell fraction is markedly higher.

Conclusions:

This study shows the potential of metabolic HP 13C-MRI to characterise FHd-RCC and how targeting of biopsies to regions of metabolic dysregulation could be used to obtain the tumour samples of greatest clinical significance, which in turn can inform on early and successful response to treatment.